Literature DB >> 20132920

Potent adaptive immune responses induced against HIV-1 gp140 and influenza virus HA by a polyanionic carbomer.

George Krashias1, Anna-Katharina Simon, Frank Wegmann, Wai-Ling Kok, Ling-Pei Ho, David Stevens, John Skehel, Jonathan L Heeney, Amin E Moghaddam, Quentin J Sattentau.   

Abstract

Carbopol is a polyanionic carbomer gel used in man for a variety of topical applications and drug delivery purposes. Here we show that subcutaneous administration of carbopol with glycoprotein antigens elicits unusually strong specific adaptive immune responses in mice. Recombinant soluble HIV-1 envelope glycoprotein (Env)-based antigen formulated in carbopol was at least as potent at stimulating Env-specific B and T cell responses as Freund's Complete Adjuvant, and significantly more potent than aluminium salts. The antigen-specific T cell immune response elicited both Th1 and Th2 cytokines including high titers of IFN-gamma, IL-2 and IL-4, and drove a Th1 isotype-switched antibody response. Mice immunized with a low dose of purified influenza HA in carbopol generated high titers of anti-HA antibodies and were protected from lethal challenge and disease with live virus. Similarly, immunization of mice with the melanoma cell line B16F10 formulated in carbopol significantly delayed tumor growth. We propose that carbopol, or related cross-linked polyacrylic acid analogues, may have promise for use as systemic vaccine adjuvants in man. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20132920     DOI: 10.1016/j.vaccine.2010.01.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett
Journal:  Vaccine       Date:  2012-02-22       Impact factor: 3.641

2.  Combination Adjuvants Affect the Magnitude of Effector-Like Memory CD8 T Cells and Protection against Listeriosis.

Authors:  Woojong Lee; Autumn Larsen; Brock Kingstad-Bakke; Chandranaik B Marinaik; M Suresh
Journal:  Infect Immun       Date:  2021-06-16       Impact factor: 3.441

3.  Transfer of Mycoplasma hyopneumoniae-specific cell mediated immunity to neonatal piglets.

Authors:  Bert Devriendt; Dominiek Maes; Evelien Biebaut; Lisa Beuckelaere; Filip Boyen; Freddy Haesebrouck; Charles-Oliver Gomez-Duran
Journal:  Vet Res       Date:  2021-06-30       Impact factor: 3.683

Review 4.  Current and novel approaches to vaccine development against tuberculosis.

Authors:  Mark J Cayabyab; Lilia Macovei; Antonio Campos-Neto
Journal:  Front Cell Infect Microbiol       Date:  2012-12-06       Impact factor: 5.293

5.  Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally.

Authors:  David J Lewis; Carol A Fraser; Abdel N Mahmoud; Rebecca C Wiggins; Maria Woodrow; Alethea Cope; Chun Cai; Rafaela Giemza; Simon A Jeffs; Maria Manoussaka; Tom Cole; Martin P Cranage; Robin J Shattock; Charles J Lacey
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

6.  Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen.

Authors:  J F S Mann; D Stieh; K Klein; D S Miranda de Stegmann; M P Cranage; R J Shattock; P F McKay
Journal:  J Control Release       Date:  2011-11-15       Impact factor: 9.776

7.  Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.

Authors:  Rachel P J Lai; Michael S Seaman; Paul Tonks; Frank Wegmann; David J Seilly; Simon D W Frost; Celia C LaBranche; David C Montefiori; Antu K Dey; Indresh K Srivastava; Quentin Sattentau; Susan W Barnett; Jonathan L Heeney
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

8.  The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice.

Authors:  Frank Wegmann; Amin E Moghaddam; Torben Schiffner; Kate H Gartlan; Timothy J Powell; Rebecca A Russell; Matthijs Baart; Emily W Carrow; Quentin J Sattentau
Journal:  Clin Vaccine Immunol       Date:  2015-07-01

9.  Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.

Authors:  T Schiffner; L Kong; C J A Duncan; J W Back; J J Benschop; X Shen; P S Huang; G B Stewart-Jones; J DeStefano; M S Seaman; G D Tomaras; D C Montefiori; W R Schief; Q J Sattentau
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

10.  Conjugation, characterization and toxicity of lipophosphoglycan-polyacrylic acid conjugate for vaccination against leishmaniasis.

Authors:  Murat Topuzogullari; Rabia Cakir Koc; Sevil Dincer Isoglu; Melahat Bagirova; Zeynep Akdeste; Serhat Elcicek; Olga N Oztel; Serap Yesilkir Baydar; Sezen Canim Ates; Adil M Allahverdiyev
Journal:  J Biomed Sci       Date:  2013-06-03       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.